INTRODUCTION 48
Millions of people are at risk of contracting human African trypanosomiasis (HAT), a disease 49 that is caused by the protozoan Trypanosoma brucei. Current chemotherapies cannot be 50 administered orally, and some are toxic (1) . Consequently, a pressing need exists for new 51 therapeutics with oral bioavailability and adequate safety profiles (2). 52 53 Rational design of drugs to inhibit the function of proteins that are essential for cell viability has 54 an important place in the hunt for new anti-trypanosome pharmaceutics (3-5). Investigators who 55 suspect that a protein is "druggable" face numerous challenges throughout the course of drug 56 design and development (6-8). First, genetics must be used to validate the candidate protein as 57 a bona fide drug target (4, 8). Second, small molecule inhibitors of the protein target must be 58 identified. Third, the inhibitors must be selectively toxic to parasite cells. Fourth, the inhibitor 59 structure must be optimized reiteratively in a medicinal chemistry campaign to identify 60 compounds with the best balance of potency, selectivity, and pharmacokinetic properties. Fifth, 61 a human safety trial (phase I) must be conducted to determine whether the chemical entity can 62 become a drug, followed by phase II studies involving patients with the disease. Unfortunately, 63 most genetically validated putative parasite "drug targets" have failed to produce drugs because 64 (i) small molecule inhibitors of the "druggable target" have not been found, and/or (ii) the4 clinical use are not optimized against parasite targets; therefore medicines that can work well7 (density <10 6 /ml) under standard conditions (5% CO 2 and 37°C), and were sub-cultured every 151 1-2 days, by seeding trypanosomes at 10 4 /ml or 10 3 /ml respectively 152 153
Trypanosome replication and drug susceptibility assays in vitro 154
Drugs were tested initially at 400 nM or 4 µM to define the range of concentrations for 155 subsequent assays. T. brucei from a mid-log phase culture were diluted into pre-warmed HMI-9 156 medium (1 ml) at 2 x 10 3 cells/ml in each well of 24-well plates. DMSO or drugs (in 2 µl) were 157 added from appropriate working solutions to the specified final concentrations. After 48 h 158 incubation, cell density was determined with a haemocytometer. Cell density as a function of 159 drug concentration was plotted with Excel (Microsoft), and GI 50 for each drug was calculated 160 using the equation of the trend line from the data. Standard deviation reported was from a total 161 of four separate measurements obtained from two independent experiments. 162 163
Short-term 6h drug exposure for trypanosome killing assays 164
Stocks of drugs with exception of pentamidine were prepared in DMSO; pentamidine was in 165 sterile distilled water. One ml of T. brucei (1x10 5 cells/ml) was aliquoted into 24-well plates and 166 1 μl of drug solution added (to a final concentration 5 μM). An equal volume of DMSO or water 167 was added to control samples. Following incubation for 6 h (5% CO 2 , 37 o C) cell suspensions 168 were concentrated 10-fold by centrifugation (3000 xg, 5 min, room temperature) followed by 169 removal of all but 100 μl of supernatant. Trypanosome density was determined either with a 170 haemocytometer or in a Z2 Coulter counter (Beckman) with AccuComp software (Settings: 171 Range-2.5 μm to 5 μm, dilution factor-50, metered volume-1 ml) in duplicate. For drug testing, HeLa cells were diluted into pre-warmed DMEM medium at a density of 186 1 x 10 5 cells/ml and distributed into 24-well plates (1 ml per well), followed by 24 h incubation. 187 DMSO or drugs (5 µl) were added from appropriate working solutions to the specified final 188 concentrations, and the cells were cultured for 48 h. Each well was washed with 1 ml of PBS, 189
and incubated with 100 µl of trypsin/EDTA solution (Gibco) for 3 min at 37 o C, 5% CO 2 . DMEM 190 medium (900 µl) was added to each well, mixed, and unadhered cells were retrieved into 1.5 ml 191 polypropylene tubes. Cells (a 45 µl aliquot) were mixed with 5 µl trypan blue (0.04%) (Gibco), 192 and cell density was determined with a haemocytometer. GI 50 for each drug was calculated by 193 plotting data for the cell counts in Excel (Microsoft) as described in the previous section. haemocytometer. When parasitemia was higher than 10 7 /ml, dilutions of blood were made into 217 BSG. If no parasite was detected after 14 days, parasitemia was monitored thrice a week for 30 218 days. Mice surviving 30 days after death of the last control mouse, and having no parasitemia 219 were considered cured. Data was plotted using GraphPad Prism (GraphPad Software, La Jolla, 220 CA). 221
222

RESULTS
223
Tyrosine Kinase Drugs Reduce Replication of Cultured Bloodstream Trypanosomes 224
Tyrosine kinase inhibitors tyrphostin A47 and lapatinib inhibit replication of T. brucei (22, 23 50 's of 1.9 μM, 2.0 μM and 2.5 μM respectively. Imatinib 230 (Gleevec) (36, 37) was relatively inactive (i.e., GI 50 was greater than 10 μM) ( Table 1 and Fig.  231 1G-F). Of these drugs, CI-1033, AEE788 and lapatinib became the focus of this study because 232 their plasma concentration after oral administration to mice was known in the literature to equal 233 or exceed GI 50 in vitro. General cytoxicity of the compounds was tested by exposing a human 234
HeLa cell line to the drugs for 48 h (Fig. 1G-I ). Lapatinib with a GI 50 against HeLa (i.e., 235 GI 50 HeLa) > 20 µM was the least toxic ( Fig. 1G) , followed by AEE788 (GI 50 HeLa = 13.8 µM) (Fig.  236 1I), and CI-1033 (GI 50 HeLa = 5.4 µM) (Fig. 1H) . 237
238
We were interested in learning the contribution of cell death to overall replication inhibition ( Fig.  239 1D-F and Table 1 ). To investigate this topic, trypanosomes (10 5 /ml) were exposed to select 240 PTKI drugs (5 μM) for 6 h (the cell division time of cultured bloodstream T. brucei), and cell 241 density was determined ( Fig. 2A) . Two kinds of effects were observed-cell killing and reduced 242 replication. For lapatinib, the density of treated cells was 62% less than the starting level, so this 243 drug kills trypanosomes within 6 h. In the case of AEE788, CI-1033 and pentamidine, the 244 density of the treated cultures after 6 h exceeded the starting density. Hence these drugs did 245 not kill within 6 h. However, all three drugs reduced replication of T. brucei: trypanosome density 246 after 6 h was reduced by 46% (AEE788), 16% (CI-1033), and 10% (pentamidine) as compared 247 to control (untreated cells) ( Fig. 2A) . 248
249
Anticipating that the effects of some drugs on T. brucei might manifest well after exposure to the 250 compounds, we monitored trypanosome replication 48 h after the drugs were washed off and 251 cells seeded at the same density (10 4 /ml) (Fig. 2B) . Pentamidine was the most potent 252 compound in this delayed killing assay: no trypanosomes were detected after 48 h whereas 253 control (untreated) cells replicated to a density of 3 x 10 11 killed 78% of trypanosomes in this assay, while AEE788 and lapatinib killed 13% and 30% of 255 the parasites respectively (Fig. 2B) . 256
257
We infer from these data (Fig. 2) , that despite the similarity of the GI 50 values for lapatinib, 258 AEE788, and CI-1033 (Table 1) , lapatinib is the most promising of three because it can kill 259 trypanosomes after a short period ( Fig. 2A) . We envision that drugs that kill trypanosomes after 260 a short exposure are likely to be more effective in an animal model of the disease where the 261 drug is bound to be cleared from the blood with time. These ideas were tested in a mouse 262 model of HAT ( Table 1) by 266 trying to identify drugs with efficacy in a mouse model of HAT (i.e., "leads") (38). Drugs for this 267 study were chosen if their plasma concentration after oral administration was documented in the 268 literature to equal or exceed GI 50 in vitro (Table 1) . For example, plasma concentration of the 4-269 anilinoquinazolines (e.g., lapatinib, erlotinib, and CI-1033) could reach 4 μM (39-42) whereas 270 the GI 50 for the drugs against T. brucei is less than 2 μM (Fig. 1G-F and Table 1 ). This fact 271 suggested that the drugs might control a T. brucei infection without necessarily eliminating the 272 parasites from a mouse, because the plasma level of the drug was less than 10-times GI 50 . 273
Nevertheless, for "proof-of-principle" the study was warranted, because we could also track 274 parasites in mouse blood (i.e., parasitemia) as a measure of drug efficacy, even if a cure was 275 elusive. 276 277 Drugs were administered either orally or intraperitoneally using doses employed in murine 278 models of proliferative disease (25, 30, 43-45) (Materials and Methods). 279
12
In untreated mice, trypanosomes were usually detected in blood on day 2 post-infection, and 281 parasitemia peaked between days 5-to-7 at 10 8 /ml or 10 9 /ml. Untreated mice cannot control 282 parasitemia, succumbing to the disease with a mean survival time of about 5 days (Fig. 3C, Fig.  283 4C and Fig. 5C ). 284
285
When lapatinib was administered orally, three effects on trypanosomes in blood were observed. 286
First, whereas control mice died after parasitemia reached 10 8 /ml, lapatinib-treated mice were 287 alive with parasitemia in excess of 10 8 /ml on day 6 (Fig. 3A) . Second, on day 7 when all the 288 control mice were dead, three of the lapatinib-treated mice were alive. Third, in surviving mice, 289 the parasitemia dropped 150-fold from an average of 6 x 10 8 /ml on day 6 to 4 x 10 6 /ml on day 8 290 (Fig. 3A) . Lapatinib cured 25% of trypanosome-infected mice (Fig. 3B ) in three independent 291 studies each with 4 mice. The mean survival of the mice (excluding those that were cured) was 292 8 days (Fig. 3C) , instead of 5.5 days for control mice that were not treated with drug. The dosing 293 route for lapatinib influenced efficacy of the drug. Intraperitoneal administration of lapatinib 294 delayed onset of parasitemia (data not shown). However, that treatment regimen could not 295 eliminate the infection and all drug treated mice died by day 8. Thus, oral dosing of lapatinib 296 was superior to delivery by intraperitoneal injection for controlling T. brucei infection in mice. 297 298 CI-1033 had a modest effect on trypanosomes in the blood of infected mice (Fig. 4) . The drug 299 reduced the number of trypanosomes in blood by 20-fold on day 4 (compare the mean 300 parasitemia of 4 x 10 7 /ml in untreated mice to 2 x 10 6 /ml in drug-treated mice) (Fig. 4A) . On day 301 6, when all control mice had died, three of the CI-1033-treated mice were alive, but all of them 302 died in the next 2 days (Fig. 4B) . The mean survival of mice was 6 days compared to 4.5 days 303 for untreated mice ( Orally-administered AEE788 controlled T. brucei infection of mice (Fig. 5) . On day 7 when no 307 control mouse was alive, every AEE788-treated mouse survived (Fig. 5A and Fig. 5B ). Drug 308 treatment reduced parasitemia 100-fold from 10 9 /ml on day 7 to 10 7 /ml on day 8 (Fig. 5A) . The 309 mean survival of AEE788-treated mice increased to 10 days from to 5.5 days for untreated mice 310 (Fig. 5B and Fig. 5C ). When the drug was administered intraperitoneally, parasitemia was 311 reduced initially, but the mice died with low parasitemia, and their mean survival time was 312 similar to that of untreated mice (data not shown). We leveraged this basic biological observation (above) for lead discovery, by mining the 340 literature for drugs that target PTKs in humans (reviewed in (13, 54)) as possible "hits" for anti-341 trypanosome drug discovery. This approach enables a "focused screen" using only several 342 small molecules (i.e., less than 10) instead of thousands of small molecules needed for high 343 throughput initiatives. Remarkably the "hit" discovery rate with the "focused screen" strategy 344 (Stage 1) was very high: 7 out of 8 molecules examined were active (see Table 1 ), emphatically 345 validating our approach. We emphasize that we are not advocating that the "hits" be used 346
352
In a "proof-of-principle" study using a mouse model of HAT (i.e. Stage 2, Lead Discovery of our 353 "Scaffold Repurposing" blueprint), three measures were used to assess whether or not the hits 354 (Table 1) Lapatinib met all 3 tests (above): it reduced the number of trypanosomes in the mouse (Fig. 3) , 360
and cured 25% of trypanosome-infected mice in three independent experiments. This result 361 exceeded expectations because the drug was optimized against a human EGFR type 2 (HER2) 362 (55); it was neither optimized against a trypanosome protein nor tested in a phenotypic screen 363 against T. brucei. Although T. brucei lacks HER2, lapatinib binds four trypanosome protein 364 kinases (22) three of which are essential for viability of the parasite (56-58). Therefore, it is 365 16 conceivable that the drug modulates activity of one or more of those enzymes in killing and 366 controlling the trypanosome infection. 367 368 CI-1033 is a 4-anilinoquinazoline derivative (30), like lapatinib. In the in vitro cell replication 369 assay, CI-1033 had a GI 50 in the same range as lapatinib (Table 1) . However, CI-1033 370 dramatically underperformed lapatinib in the mouse model of HAT (Fig. 4) . The reason for this 371 large difference in performance of the two drugs might lie in different pharmacokinetics and 372 distribution of the drugs in a mouse, which is most likely influenced by the chemical substituents 373 on the common 4-anilinoquinazoline scaffold of the drugs (20, 30) (see Fig. 1A ). The borderline 374 efficacy of CI-1033 could also be ascribed to our use of a lower amount of drug and less 375 frequent doses; 30 mg/kg once daily compared to 100 mg/kg twice daily for lapatinib. We had to 376 use a lower amount of CI-1033 because higher amounts are toxic to mice-an observation 377 supported by our in vitro studies with HeLa cells (Fig 1G-H) . Either way, these observations 378 highlight the notion that new synthetic 4-anilinoquinazoline derivatives could be produced 379 against T. brucei using lessons learned from comparing the structures of lapatinib and CI-1033. 380
In support of this principle, the Pollastri group has synthesized nine new lapatinib-derivatives 381 that are 5 -30 times more potent than lapatinib in whole cell screening assays (28). Thus, the 4-382 anilinoquinazoline is a good scaffold for anti-trypanosome lead optimization. 383 384 AEE788 (25) was equipotent with lapatinib in reducing parasitemia but failed to cure 385 trypanosome-infected mice (Fig. 5) . The strong reduction of parasitemia during oral 386 administration of AEE788 treatment suggests that a pyrrolopyrimidine scaffold (also present in 387 PKI-166 (Table 1) 
